KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus" or “The Company”), today announced that an article on the use of PV-10 for in-transit melanoma has been published by the Journal of Surgical Oncology. It expands on a presentation on the same topic given at the Royal Australasian College of Surgeons 85th Annual Scientific Congress, which was held 2-6 May 2016, in Brisbane, Australia.
Publications
Scientific Journals for May 2016
Journal of National Cancer Institute Oncolytic Virus Approved To Treat Melanoma By Charlie Schmidt JNCI J Natl Cancer Inst (2016)108 (5): djw140doi: 10.1093/jnci/djw140 Cancer Biotherapy and Radiopharmaceuticals Robert O. Dillman. Long-Term Progression-Free and Overall Survival in…
Read More Nivolumab/Ipilimumab Combo Approved in Europe for Advanced Melanoma
The European Commission has approved the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) as a treatment for patients with unresectable or metastatic melanoma regardless of BRAF status, based on data from the CheckMate-069 and -067 studies.
Scientific Journals for April 2016
Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay